CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 177 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is 0.81 and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,540,294 | +93.7% | 51,792 | +17.3% | 0.00% | – |
| Q2 2023 | $795,313 | +59.8% | 44,135 | +42.4% | 0.00% | – |
| Q1 2023 | $497,603 | +6420.8% | 30,984 | +7330.2% | 0.00% | – |
| Q4 2022 | $7,631 | -59.8% | 417 | -57.3% | 0.00% | – |
| Q3 2022 | $19,000 | -29.6% | 976 | -35.8% | 0.00% | – |
| Q2 2022 | $27,000 | -80.0% | 1,521 | -75.3% | 0.00% | – |
| Q1 2022 | $135,000 | -78.5% | 6,156 | -72.2% | 0.00% | – |
| Q4 2021 | $628,000 | +694.9% | 22,115 | +325.7% | 0.00% | – |
| Q1 2021 | $79,000 | -75.8% | 5,195 | -77.6% | 0.00% | – |
| Q4 2020 | $327,000 | +5.1% | 23,193 | +16.9% | 0.00% | – |
| Q3 2020 | $311,000 | -12.4% | 19,839 | -2.1% | 0.00% | – |
| Q2 2020 | $355,000 | +258.6% | 20,256 | +199.7% | 0.00% | – |
| Q1 2020 | $99,000 | -57.3% | 6,759 | -27.1% | 0.00% | – |
| Q4 2019 | $232,000 | -33.9% | 9,275 | -60.2% | 0.00% | – |
| Q3 2019 | $351,000 | -30.5% | 23,309 | +15.4% | 0.00% | – |
| Q2 2019 | $505,000 | +117.7% | 20,199 | +98.0% | 0.00% | – |
| Q1 2019 | $232,000 | -23.4% | 10,200 | +0.9% | 0.00% | – |
| Q4 2018 | $303,000 | +212.4% | 10,105 | +198.5% | 0.00% | – |
| Q3 2018 | $97,000 | – | 3,385 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 410,360 | $11,658,000 | 6.24% |
| 5AM Venture Management, LLC | 862,286 | $24,498,000 | 4.60% |
| Bain Capital Life Sciences Investors, LLC | 2,029,701 | $57,664,000 | 4.57% |
| Opaleye Management Inc. | 724,400 | $20,580,000 | 4.36% |
| Deep Track Capital, LP | 1,900,000 | $53,979,000 | 3.81% |
| BVF INC/IL | 3,003,879 | $85,340,000 | 3.10% |
| FRAZIER MANAGEMENT LLC | 1,384,293 | $39,328,000 | 3.03% |
| Altium Capital Management LP | 331,000 | $9,404,000 | 2.59% |
| Perceptive Advisors | 10,327,034 | $293,392,000 | 2.26% |
| MPM BioImpact LLC | 379,792 | $10,790,000 | 1.97% |